An estimated 70% of asthma patients don’t take their medication as prescribed, predominantly because adherence is unnecessarily complicated. Our technology answers a simple need: the need for simplicity when it comes to using the inhaler correctly and effectively managing asthma.

Our AcuFlo technology enables estimation of inhalation flow patterns by using acoustic signal processing and machine learning. The technology can be adapted to work with both commercial MDI and DPI inhalers and also drug delivery systems being developed for treatment of COVID 19 and other respiratory disorders.